Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice

1997 ◽  
Vol 40 (10) ◽  
pp. 1195-1204 ◽  
Author(s):  
Juergen Ruhlmann ◽  
Axel Schomburg ◽  
Hans Bender ◽  
Peter Oehr ◽  
Gerda-Marie Robertz-Vaupel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Positron Emission Tomography ◽  
Cancer Patients ◽  
Daily Practice ◽  
Emission Tomography ◽  
Whole Body ◽  
Positron Emission ◽  
Colorectal Cancer Patients

Positron Emission Tomography Affects Surgical Management in Recurrent Colorectal Cancer Patients

2003 ◽  
Vol 10 (1) ◽  
pp. 59-64 ◽  
Author(s):  
Darius C. Desai ◽  
Emanuel E. Zervos ◽  
Mark W. Arnold ◽  
William E. Burak ◽  
Joseph Mantil ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Positron Emission Tomography ◽  
Cancer Patients ◽  
Surgical Management ◽  
Emission Tomography ◽  
Recurrent Colorectal Cancer ◽  
Positron Emission ◽  
Colorectal Cancer Patients

Additional Value of Whole-Body Positron Emission Tomography With Fluorine-18-2-Fluoro-2-deoxy-d-glucose in Recurrent Colorectal Cancer

1999 ◽  
Vol 17 (3) ◽  
pp. 894-894 ◽  
Author(s):  
Patrick Flamen ◽  
Sigrid Stroobants ◽  
Eric Van Cutsem ◽  
Patrick Dupont ◽  
Guy Bormans ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Diagnostic Value ◽  
Diagnostic Methods ◽  
Emission Tomography ◽  
Whole Body ◽  
Positron Emission ◽  
Additional Value

PURPOSE: To assess the additional value of the whole-body [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) scan as a staging modality complementing conventional diagnostic methods (CDM) in patients suspected of having recurrent colorectal adenocarcinoma. PATIENTS AND METHODS: In 103 patients, the discordances between FDG-PET and CDM results were identified and related to the final diagnosis obtained by histopathology or clinical follow-up (> 1 year). All FDG-PET studies were reviewed with full knowledge of the CDM findings. RESULTS: In a region-based analysis, discordances between CDM and FDG-PET findings were found in 40 of 412 regions (10%). In these, FDG-PET had additional diagnostic value in 14 of 16 locoregional, six of seven hepatic, seven of eight abdominal, and eight of nine extra-abdominal regions. In a patient-based analysis, CDM categorized a subgroup of 60 patients as having resectable recurrent disease limited to the liver (n = 37) or locoregional region (n = 23). In 13 of these patients, there were discordant FDG-PET findings, detecting additional tumor sites in nine patients and excluding disease in three patients and yielding an additional diagnostic value in 20% of the patients. A second subgroup consisted of 13 patients with inconclusive CDM findings (n = 5) or with elevated plasma carcinoembryonic antigen levels and an otherwise negative conventional work-up (n = 8). In these patients, FDG-PET results were correct in eight of nine discordances, yielding a positive additional diagnostic value in 62% of the patients. CONCLUSION: Whole-body FDG-PET can have a clear impact on the therapeutic management in the follow-up of patients with colorectal cancer.

Sign in / Sign up

Export Citation Format

Share Document